Provided herein are compositions (e.g., killer cell immunoglobulin-like receptor (KIR)-targeting agents) that target a subset of T lymphocytes present in disease states (e.g., lupus and other autoimmune diseases) and methods of treating conditions and/or diseases therewith. In particular, anti-KIR antibodies, fragments thereof, or related compositions are provided for the treatment of conditions and/or diseases (e.g., lupus and other autoimmune diseases, atherosclerosis, etc.).
